This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Senesco Technologies Reports Fiscal 2012 Third Quarter Results

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the third quarter of fiscal year 2012 which ended on March 31, 2012.

Highlights of the third quarter and recent weeks include:

  • Combination of lenalidomide and SNS01-T eliminated tumors in over 80% of animals treated in a mouse xenograft model of multiple myeloma;
  • Senesco added two additional clinical sites to enhance enrollment into the SNS01-T clinical trial to treat multiple myeloma;
  • In March, Senesco raised an additional $1 million in equity financing to add to approximately $2M raised in January 2012; and
  • BioCorp Ventures and Senesco entered into a license agreement for the application of eIF5A to sustainable energy applications.

“We are pleased with the progress we have made in the development of SNS01-T, and look to accelerate enrollment in the clinical trial with the two additional sites we added this past quarter,” said Leslie J. Browne, Ph.D., President and CEO of Senesco. “It is exciting to see how well SNS01-T has performed alone and in combination with lenalidomide, the active ingredient of REVLIMID ® by completely eradicating myeloma tumors in 83% of the treated animals that received SNS01-T combined with the optimal study dose of lenalidomide.”

Third Quarter Fiscal 2012 Financial Results

There was no revenue for the three month period ending March 31, 2012 and March 31 2011.

Research and development expenses for the three month period ended March 31, 2012 were $540,789 compared with $800,341 for the three month period ended March 31, 2011, a decrease of 32%. The decrease was primarily due to a decrease in the costs incurred in connection with the development of SNS01-T for multiple myeloma. Specifically, during the three month period ended March 31, 2011, the Company incurred significant costs related to the filing and follow up of its investigational new drug application and other preclinical work that Senesco did not incur during the three month period ended March 31, 2012.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs